By targeting a previously undiscovered allosteric site on a DMD-associated enzyme, researchers found muscle cell conditions improved.
List view / Grid view
Filter the results
Enzymes are macromolecular biological catalysts. Enzymes accelerate, or catalyse, chemical reactions.
So you have performed your screen. What’s next? This guide is focused on how biochemical assays are used for characterising and prioritising compounds.
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
Scientists have developed a synthetic biology process using enzymes to create three families of terpenes, potential starting points for new drugs.
A molecule called TPPU has been shown to inhibit an enzyme that plays a key role in inflammation, successfully treating arthritis in mice.
A flow mode Raman-activated cell sorter called FlowRACS has been created by researchers for high-throughput discovery of enzymes and their cell factories.
Researchers have found the TBK1 enzyme regulates the degradation and clearance of the huntingtin protein, making it a drug target for Huntington's disease.
A new FXII inhibitor has been developed that efficiently blocked coagulation in a thrombosis model without increasing the risk of bleeding.
A team has shown that inhibiting the soluble epoxide hydrolase (sEH) enzyme in murine models can prevent the cognitive deterioration associated with Alzheimer's.
The novel CRISPR-CasΦ enzyme, isolated from bacteriophages, can target a wider range of genetic sequences, say the researchers.
Researchers found breast cancer cells reprogrammed natural killer T cells, altering gene expression and receptor expression so they help cancerous metastases spread.
Scientists identified a novel, highly specific drug target in the enzyme (sterol O-acyltransferase 1 (SOAT1)) cancer cells use to store cholesterol.
Dr Sarah Doyle and Dr Ema Ozaki outline their research into SARM1 and why it presents an attractive target for treating retinal degeneration.